决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells.
本研究为加强免疫治疗的早期筛选以促进其开发提供了一种新的潜在方法,并以高度相关的细胞模型进行了验证。
背景:为加快新型免疫治疗方法的转化,有必要在体外早期阶段开发评估其疗效的分析方法。我们利用基于液滴的微流控平台,建立了一种可对免疫疗法进行多参数、可量化表型和基因组观察的方法。嵌合抗原受体(CAR)自然杀伤(NK)细胞在当前免疫治疗领域受到越来越多关注,因此适合作为评估这一新方法的模型。方法:在此方法中,比较经 CD19 CAR 转导的 NK 细胞与未转导 NK 细胞杀伤淋巴瘤细胞系的能力。利用微流控平台,我们定量发现 CAR-NK 细胞的细胞毒作用和突触接触形成均高于未转导 NK 细胞。随后,我们优化液滴分选仪,成功根据 NK 细胞对靶细胞的杀伤能力进行分选,并开展转录组分析。结果:数据证实 CD19 CAR 可预期地提高细胞毒性,更重要的是,还揭示了 CAR-NK 细胞细胞毒机制相关因素的新见解。这展示了一种新型且改良的系统,可加速未来免疫治疗的临床前筛选。结论:本研究提供了一种可能用于增强免疫疗法早期筛选的新方法,有助于改善其开发,并采用高度相关的细胞模型加以演示。此外,验证研究还为影响 CAR-NK 细胞毒性的转录组决定因素提供了一些潜在见解。
BACKGROUND: To accelerate the translation of novel immunotherapeutic treatment approaches, the development of analytic methods to assess their efficacy at early in vitro stages is necessary. Using a droplet-based microfluidic platform, we have established a method for multiparameter quantifiable phenotypic and genomic observations of immunotherapies. Chimeric antigen receptor (CAR) natural killer (NK) cells are of increased interest in the current immunotherapy landscape and thus provide an optimal model for evaluating our novel methodology. METHODS: For this approach, NK cells transduced with a CD19 CAR were compared with non-transduced NK cells in their ability to kill a lymphoma cell line. Using our microfluidic platform, we were able to quantify the increase in cytotoxicity and synaptic contact formation of CAR NK cells over non-transduced NK cells. We then optimized our droplet sorter and successfully used it to separate NK cells based on target cell killing to perform transcriptomic analyses. RESULTS: Our data revealed expected improvement in cytotoxicity with the CD19 CAR but more importantly, provided unique insights into the factors involved in the cytotoxic mechanisms of CAR NK cells. This demonstrates a novel, improved system for accelerating the pre-clinical screening of future immunotherapy treatments. CONCLUSIONS: This study provides a new potential approach for enhanced early screening of immunotherapies to improve their development, with a highly relevant cell model to demonstrate. Additionally, our validation studies provided some potential insights into transcriptomic determinants influencing CAR NK cytotoxicity.
MEMBER ACCOUNT
登录成功会直接打开下一页。